PubMedID: 24299454Metformin is a biguanide group oral antidiabetic drug used for the treatment of type 2 diabetes mellitus. Nausea, vomiting, diarrhea, abdominal pain, and anorexia are the most common adverse effects encountered during treatment. Lactic acidosis is a serious side effect seen with metformin use, and while the incidence of lactic acidosis is similar to other oral antidiabetics, metformin is not recommended to patients with certain risk factors, such as cardiovascular, pulmonary, and renal and liver failure. We describe a chronic hemodialysis patient treated with metformin, presenting to the nephrology department with altered mental status. © 2013 International Society for Hemodialysis
Metformin biguanid sınıfından, Tip 2 diyabetiklerde, özellikle böbrek fonksiyonları normal hastalard...
International audienceMetformin associated lactic acidosis (MALA) is a serious complication occurrin...
peer reviewedMetformin is an oral antidiabetic largely prescribed in the treatment of type II diabet...
Metformin is an oral antidiabetic from biguanide class and is the first-line treatment option f...
Metformin is a biguanide commonly used in type 2 diabetes mellitus (DM). Lactic acidosis, a potentia...
Metformin is a biguanide used in the treatment of type 2 diabetic patients with normal renal functio...
Metformin, the only biguanide available in France, is a widely prescribed anti-diabetic agent. It im...
Metformin is an oral antidiabetic drug in the biguanide class, which is used for type 2 diabetes. Th...
Metformin is an oral antidiabetic drug in the biguanide class, which is used for type 2 diabetes. Th...
Metformin is a widely used antihyperglycemic agent recommended by both the American Diabetes Associa...
Metformin is recommended as a first-line treatment for patients with diabetes mellitus type 2; it ha...
Metformin-associated lactic acidosis in a diabetic patient is a rare and severe complication. The se...
Metformin is a safe drug when correctly used in properly selected patients. However, in real life, a...
BACKGROUND: Lactic acidosis in metformin use is a widely recognised but rare side effect. Case repor...
Metformin is commonly used in the treatment of type 2 diabetes mellitus (DM). Severe lactic acidosis...
Metformin biguanid sınıfından, Tip 2 diyabetiklerde, özellikle böbrek fonksiyonları normal hastalard...
International audienceMetformin associated lactic acidosis (MALA) is a serious complication occurrin...
peer reviewedMetformin is an oral antidiabetic largely prescribed in the treatment of type II diabet...
Metformin is an oral antidiabetic from biguanide class and is the first-line treatment option f...
Metformin is a biguanide commonly used in type 2 diabetes mellitus (DM). Lactic acidosis, a potentia...
Metformin is a biguanide used in the treatment of type 2 diabetic patients with normal renal functio...
Metformin, the only biguanide available in France, is a widely prescribed anti-diabetic agent. It im...
Metformin is an oral antidiabetic drug in the biguanide class, which is used for type 2 diabetes. Th...
Metformin is an oral antidiabetic drug in the biguanide class, which is used for type 2 diabetes. Th...
Metformin is a widely used antihyperglycemic agent recommended by both the American Diabetes Associa...
Metformin is recommended as a first-line treatment for patients with diabetes mellitus type 2; it ha...
Metformin-associated lactic acidosis in a diabetic patient is a rare and severe complication. The se...
Metformin is a safe drug when correctly used in properly selected patients. However, in real life, a...
BACKGROUND: Lactic acidosis in metformin use is a widely recognised but rare side effect. Case repor...
Metformin is commonly used in the treatment of type 2 diabetes mellitus (DM). Severe lactic acidosis...
Metformin biguanid sınıfından, Tip 2 diyabetiklerde, özellikle böbrek fonksiyonları normal hastalard...
International audienceMetformin associated lactic acidosis (MALA) is a serious complication occurrin...
peer reviewedMetformin is an oral antidiabetic largely prescribed in the treatment of type II diabet...